Pfizer's (PFE) Talzenna plus Xtandi significantly improves radiographic progression-free survival in metastatic prostate cancer; meets primary endpoint with significant improvement in RPFS
Importance
Level 1
#PFIZER INC#PFE.US#EQUITIES#EU SESSION#PHARMACEUTICALS#PHARMACEUTICALS (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#PFE#US EQUITIES